Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
- 15 May 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (10), 4309-4318
- https://doi.org/10.1158/0008-5472.can-08-4102
Abstract
To study the immune response to prostate cancer, we developed an autochthonous animal model based on the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse in which spontaneously developing tumors express influenza hemagglutinin as a unique, tumor-associated antigen. Our prior studies in these animals showed immunologic tolerance to hemagglutinin, mirroring the clinical situation in patients with cancer who are generally nonresponsive to their disease. We used this physiologically relevant animal model to assess the immunomodulatory effects of cyclophosphamide when administered in combination with an allogeneic, cell-based granulocyte-macrophage colony-stimulating factor–secreting cancer immunotherapy. Through adoptive transfer of prostate/prostate cancer–specific CD8 T cells as well as through studies of the endogenous T-cell repertoire, we found that cyclophosphamide induced a marked augmentation of the antitumor immune response. This effect was strongly dependent on both the dose and the timing of cyclophosphamide administration. Mechanistic studies showed that immune augmentation by cyclophosphamide was associated with a transient depletion of regulatory T cells in the tumor draining lymph nodes but not in the peripheral circulation. Interestingly, we also noted effects on dendritic cell phenotype; low-dose cyclophosphamide was associated with increased expression of dendritic cell maturation markers. Taken together, these data clarify the dose, timing, and mechanism of action by which immunomodulatory cyclophosphamide can be translated to a clinical setting in a combinatorial cancer treatment strategy. [Cancer Res 2009;69(10):4309–18]Other Versions
This publication has 50 references indexed in Scilit:
- Rapid tolerization of virus-activated tumor-specific CD8 + T cells in prostate tumors of TRAMP miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Foxp3+natural regulatory T cells preferentially form aggregates on dendritic cellsin vitroand actively inhibit their maturationProceedings of the National Academy of Sciences of the United States of America, 2008
- How regulatory T cells workNature Reviews Immunology, 2008
- Comparative methodologies of regulatory T cell depletion in a murine melanoma modelJournal of Immunological Methods, 2008
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune ActivationClinical Cancer Research, 2008
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJCI Insight, 2007
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsBlood, 2007
- Viral Alteration of Cellular Translational Machinery Increases Defective Ribosomal ProductsJournal of Virology, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJCI Insight, 2006